Indian pharma company Lupin Limited has launched Tavaborole Topical Solution, 5% following regulatory approval from the US Food and Drug Administration (FDA).

Tavaborole Topical Solution, 5%, is a generic version of Kerydin Topical Solution, 5%, owned by Anacor Pharmaceuticals.

It is an oxaborole antifungal, which has been approved by the FDA for the topical treatment of onychomycosis of the toenails caused by Trichophyton rubrum or Trichophyton mentagrophytes.

As per IQVIA MAT May 2021, Tavaborole Topical Solution 5% has a projected annual sales of $53 million in the US.

Tavaborole Topical Solution, 5%, will be manufactured by Lupin Limited at its facility in Pithampur, India.

Recently, the Indian pharma company had secured tentative approval from the FDA for the generic of HIV drug cocktail – Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets.

  Anacor Pharmaceuticals, India, Kerydin Topical Solution, Lupin, Pithampur, Tavaborole Topical Solution, Trichophyton mentagrophytes, Trichophyton rubrum, US FDA